Sage nixes program for Parkinson’s disease after Phase 2 failure

Sage Ther­a­peu­tics is ter­mi­nat­ing the de­vel­op­ment of its drug dalzanem­dor in Parkin­son’s dis­ease af­ter a mid-stage test end­ed in dis­ap­point­ment.

The Phase 2 PRECE­DENT tri­al com­pared the drug with place­bo in 86 Parkin­son’s pa­tients with mild cog­ni­tive im­pair­ment. It missed its pri­ma­ry end­point, fail­ing to show a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in the Wech­sler Adult In­tel­li­gence Scale Fourth Edi­tion-IV Cod­ing Test score at 42 days ver­sus place­bo, ac­cord­ing to a Wednes­day re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.